摘要
目的:本研究旨在检测鼻咽癌患者治疗前血清中MTA1的水平,探讨其与临床特征及预后的关系。方法:收集2011年3月至2015年4月在我院治疗的初诊无转移鼻咽癌患者96例的临床资料及治疗前血清标本。利用ELISA方法测定血清MTA1浓度,以中位浓度为截断值,将患者分为低表达组和高表达组,采用单因素和多因素方法分析治疗前患者血清中MTA1浓度与临床病理特征及生存率的关系。结果:全组患者血清MTA1中位浓度为112 pg/ml(0~8215 pg/ml),中位随访47个月,23例患者发生远处转移,治疗前MTA1水平与远处转移相关(P=0.031),但与性别、年龄、T、N分期及临床分期均无关。生存率分析显示,MTA1高表达组4年DMFS为73.2%,显著低于MTA1低表达组的86.7%(P=0.039);MTA1高表达组与低表达组患者4年PFS分别为70.8%和87.3%,趋向于有统计学意义(P=0.054);尽管MTA1高表达患者4年OS低于MTA1低表达患者,但差异无显著统计学意义(82.1%vs 86.9%,P=0.091)。多因素分析表明:治疗前患者血清MTA1表达水平并不是鼻咽癌患者OS、PFS及DMFS的独立预后因素(P=0.349、P=0.126、P=0.106)。结论:鼻咽癌患者治疗前血清MTA1高表达与无转移生存相关。
Objective:To detect the level of MTA1 in the serum of patients with nasopharyngeal carcinoma and to explore its correlation with clinical characteristic and the prognosis.Methods:Pretreatment serum specimens and clinical data were collected from 96 patients who were newly diagnosed with non-metastatic NPC in our hospital from March 2011 to April 2015.The expression of serum MTA1 was detected by ELISA and classified into low or high-expression using a 50%cut-off level.The relationships of MTA1 with clinical characteristics and survival of patients were analyzed by univariate and multivariate analysis.Results:The median concentration of serum MTA1 in the whole group was 112 pg/ml(0~8215 pg/ml).The median follow-up time was 47 months.23 patients developed distant metastasis.The level of MTA1 was related to distant metastasis(P=0.031),but there was no relation between MTA1 and gender,age,T,N stage and clinical stage.Univariate survival analysis showed that the 4-year DMFS in MTA1 high-expression group was 73.2%,which was significantly lower than that in MTA1 low-expression group 86.7%(P=0.039).The 4-year PFS in MTA1 high-expression group and MTA1 low-expression group tended to be significant difference(70.8%vs 87.3%,P=0.054).Although the 4-year OS in MTA1 high-expression group was poor than that in MTA1 low-expression group,there was no significance(82.1%vs 86.9%,P=0.091).Furthermore,multivariate analysis revealed that pretreatment serum MTA1 expression was not an independent prognostic factor for DMFS,PFS and OS of NPC patients(P=0.106,P=0.126,P=0.349).Conclusion:The high expression of pretreatment serum MTA1 is related with DMFS of NPC patients.
作者
陶昊昀
廖恺
袁太泽
Tao Haoyun;Liao Kai;Yuan Taize(Department of Radiation Oncology,Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangdong Guangzhou 510095,China)
出处
《现代肿瘤医学》
CAS
2020年第6期926-929,共4页
Journal of Modern Oncology
基金
广州市卫生局资助项目(编号:20161A011087)
关键词
鼻咽癌
MTA1
预后
转移
nasopharyngeal carcinoma
metastasis-associated protein 1
prognosis
metastases
作者简介
陶昊昀(1991-),男,河南人,回族,医师,硕士,主要从事肿瘤的放射治疗工作。E-mail:568269305@qq.com;通讯作者:袁太泽(1978-),男,江西赣州人,博士,主任医师,主要从事肿瘤的放射治疗工作。E-mail:yuantaize@gzhmu.edu.cn。
